Trials / Completed
CompletedNCT02753712
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
A Two-arm, Randomised, Assessor-blind, Parallel Group Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) and Relvar® Ellipta® DPI on Ventilation Heterogeneity in Subjects With Partially Controlled or Uncontrolled Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Mundipharma Research Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate improvement of peripheral airway resistance (R5-R20) from baseline with fluticasone/formoterol breath actuated inhaler (BAI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluticasone/Formoterol BAI | |
| DRUG | Fluticasone/Vilanterol DPI (Relvar Ellipta DPI) |
Timeline
- Start date
- 2016-06-15
- Primary completion
- 2017-08-14
- Completion
- 2017-08-14
- First posted
- 2016-04-28
- Last updated
- 2018-10-23
Locations
16 sites across 5 countries: Australia, New Zealand, Slovakia, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02753712. Inclusion in this directory is not an endorsement.